BUSINESS

Sawai Further Delays Manufacturing Start at Trust Pharmatech Unit

January 11, 2024

Saiwai Group Holdings said on January 10 that it will further push back the resumption of manufacturing operations at its subsidiary Trust Pharmatech scheduled for this week as repair work after the earthquake is taking longer than expected.

The central Japan tremblor caused cracks in some of the buildings at Trust’s three plants in Fukui Prefecture. Although the company was originally planning to bring the sites back online for this year on January 4, it previously told Jiho that it was pushing back the date to sometime in the week of January 9 due to inspections. On January 10, Sawai said that the date will be further delayed to sometime in the week of January 15.

The recovery work for water supply/drainage systems as well as air conditions at the quake-damaged buildings is taking longer than initially expected, said the generic giant. However, there will be no drug supply issues related to this delay as there are enough products in inventory, it said.

Trust manufacturers allopurinol 100 mg tablet products and takes on some processes for esomeprazole capsules 20 mg.

Related Article

BUSINESS

By Ken Yoshino

Japan is pressing ahead with broader drug price cuts under its cost-effectiveness assessment (CEA) system, despite lingering questions over the…

By Philip Carrigan

Analysis of individual placements across 43 companies over the past 18 months paints a vivid picture of Japan’s evolving healthcare industry. This comprehensive snapshot illuminates current market demands, strategic shifts, and the enduring appeal of this pivotal Asian market.Rare Diseases…

By Kohei Hori

Members of a key reimbursement policy panel on October 28 raised no objections to expanding drug makers’ access to deliberations…

By Kohei Hori

Japan’s pharmaceutical industry asked the ruling Liberal Democratic Party (LDP) on October 29 to boost the country’s drug supply security…

By Takashi Ebisawa

Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…

Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…

Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…

The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…

Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…

Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…